316 related articles for article (PubMed ID: 22897447)
1. Treatment evaluation of liraglutide in type 2 diabetes.
Kela R; Davies MJ
Expert Opin Biol Ther; 2012 Nov; 12(11):1551-6. PubMed ID: 22897447
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide: a new treatment for type 2 diabetes.
Vilsboll T
Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide (Victoza) for type 2 diabetes.
Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
[TBL] [Abstract][Full Text] [Related]
5. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
Gross B
J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146
[TBL] [Abstract][Full Text] [Related]
6. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Trujillo JM; Nuffer W
Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
Monami M; Marchionni N; Mannucci E
Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
[TBL] [Abstract][Full Text] [Related]
8. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
Bode B
Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
[TBL] [Abstract][Full Text] [Related]
9. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
Mannucci E
G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
[No Abstract] [Full Text] [Related]
10. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
Scott LJ
Drugs; 2014 Dec; 74(18):2161-74. PubMed ID: 25367717
[TBL] [Abstract][Full Text] [Related]
11. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
Verge D; López X
Curr Diabetes Rev; 2010 Jul; 6(4):191-200. PubMed ID: 20380625
[TBL] [Abstract][Full Text] [Related]
12. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide for the treatment of type 2 diabetes: a clinical update.
Peters KR
Am J Ther; 2013; 20(2):178-88. PubMed ID: 21734532
[TBL] [Abstract][Full Text] [Related]
15. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
16. Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
Spellman CW
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S7-15. PubMed ID: 22267302
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D
Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
[TBL] [Abstract][Full Text] [Related]
18. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
[TBL] [Abstract][Full Text] [Related]
19. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
Sugii H; Matsumura Y; Inoue A; Horigome H; Matsuzaki K; Shimizu A
Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):233-41. PubMed ID: 20948161
[No Abstract] [Full Text] [Related]
[Next] [New Search]